Influence of isradipine on the maternal and fetal cardiovascular system in hypertensive disorders in pregnancy.
Nine pregnant women (aged 28.7 +/- 6.9 years) who had developed hypertension (blood pressure greater than 140/90 mm Hg) took part in an open pilot study with the new calcium antagonist isradipine. Dosage was started with 1.25 mg twice daily and was increased weekly to 2.5 mg and 5 mg twice daily until a diastolic blood pressure of less than or equal to 80 mm Hg was achieved. By the time of the last visit before term, blood pressure was significantly reduced to 129/79 mm Hg and heart rate had not altered. External cardiotocography indicated fetal well-being throughout the entire study. Doppler flow measurements showed no deterioration in A:B ratio, resistance index, and pulsatile index. All measurements in the newborn were within normal ranges. In conclusion, isradipine is a safe and effective drug for pregnant women and their fetuses in the management of hypertensive disorders in pregnancy.
Feiks
A
A
Department of Gynecology, Krankenanstalt Rudolfstiftung, Vienna, Austria.
Grünberger
W
W
Meisner
W
W
D000328:Adult; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005333:Fetus / Q000187:drug effects*; D006340:Heart Rate, Fetal / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology*; D017275:Isradipine; D010865:Pilot Projects; D010920:Placenta / Q000098:blood supply; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy / Q000503:physiopathology*; D011725:Pyridines / Q000494:pharmacology* / Q000627:therapeutic use; D012039:Regional Blood Flow / Q000187:drug effects
D000959:Antihypertensive Agents; D011725:Pyridines; D017275:Isradipine